ImmuneRegen and TGen Continue Testing Possible Treatment for Acute Radiation Syndrome or Radiotherapy Adjuvant Likely Targeting Adult Stem
Cells in Bone Marrow
SCOTTSDALE, Ariz., Aug. 27 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO), today announced that initial studies at TD2 (TGen Drug Development Services), an affiliate of The Translational Genomics Research Institute (TGen) have found ImmuneRegen's Radilex (TM) to protect mice from the near total destruction of circulating white blood cells following radiation exposure. These findings support past data and provide further insight into possible mechanisms underlying the activity of Radilex as well as suggest possible therapeutic areas in which Radilex could play a role as a potential treatment.
In previous studies of lethally irradiated mice, Radilex was shown to enhance survival and increase white blood cells in surviving animals. In the recent studies, a sub-lethal dose of radiation induced a 90-95% decrease in circulating white blood cell levels. Administered shortly following radiation exposure, Radilex was able to subsequently increase circulating levels of monocytes, granulocytes and lymphocytes in all treated animals.
"The results of this study have strengthened our confidence that Radilex(TM) may prove to be a life saving treatment candidate as well as a drug and treatment enhancement candidate," says Michael K. Wilhelm, Co-Founder and CEO of ImmuneRegen BioSciences, Inc. "We are very happy that our relationship with TGen continues to develop a promising collection of data on Radilex's ability to potentially preserve human life after lethal or sub-lethal exposure to radiation."
Low circulating white blood cell counts (leukopenia or leukocytopenia) can be due to a number of causes, among them infections (including certain viral infections such as those caused by influenza virus), autoimmune disorders, certain medications (including most cytotoxic chemotherapy), radiation and bone marrow diseases such as leukemia or myelodysplastic syndromes. Replenishment of leukocytes at early time periods following irradiation could result from proliferation and maturation of a pluripotential stem cell subset that is protected from the damaging effect of radiation. Further studies are in process to delineate the mechanism of leukocyte replenishment.
The Translational Genomics Research Institute (TGen), a non-profit 501(c)(3) organization, is focused on developing earlier diagnostics and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. TGen's research is based on personalized medicine and the institute plans to accomplish its goals through robust and disease-focused research.
About Radilex(TM) and Viprovex(R)
Radilex(TM) is the trade name used in referring to formulations of Homspera(TM) for potential indications for treatment of exposure to ionizing radiation. Viprovex(R) is the trade name used in referring to formulations of Homspera(TM) for potential indications for treatment of viral and bacterial infections. Homspera(TM) is a generic name used by the Company to describe the synthetic peptide Sar9, Met (O2)11-Substance P. Sar9, Met (O2)11-Substance P is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species. All of the Company's research and development efforts are early, pre-clinical stage and Homspera(TM), as Viprovex(R) and Radilex(TM), has only undergone exploratory studies to evaluate its biological activity in small animals.
About ImmuneRegen BioSciences, Inc.
IR BioSciences Holdings, Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera(TM) and its derivatives Radilex(TM) and Viprovex(R), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera(TM) is derived from Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system. For more information, please visit the company's website at http://www.immuneregen.com.
Statements about the Company's future expectations, including statements about the potential for the Company's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. The Company's actual results could differ materially from expected results as a result of a number of factors, including the fact that preliminary results involved only a small number of test mice, the subsequent investigations were limited in scope, the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs, (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials) the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in the Company's periodic report on Form 10-QSB for the three months ended June 30, 2007 and on Form 10-KSB for the twelve months ended December 31, 2006 as filed with the Securities and Exchange Commission. There are no guarantees that any of the Company's proposed products will prove to be commercially successful. The Company undertakes no duty to update forward-looking statements.
W. Jason Grimley
|SOURCE ImmuneRegen BioSciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved